Market Review and Trends
Highlights of Catalist Stocks with Strongest 5-Year Market Cap Growth
By SGX My Gateway  •  October 23, 2017
Singapore Medical Group, a private specialist and primary healthcare provider in Singapore, registered a market capitalisation growth of 17.4 times, with its market cap rising from S$16.0 million to S$278.0 million in 5 years. Moya Holdings Asia, one of leading private players in Indonesia’s water treatment industry, registered a market capitalisation growth of 8.6 times, with its market cap rising from S$32.1 million to S$274.5 million in 5 years. 800 Super Holdings, an established environmental services provider for public and private sectors in Singapore, registered a market capitalisation growth of 6.4 times, with its market cap rising from S$34.9 million to S$221.7 million in 5 years. Launched in 2007 and replacing SESDAQ, SGX’s Catalist board celebrates its 10th anniversary this year. Catalist provides investors access to smaller-sized, yet potentially fast-growing companies and allows less mature and developing enterprises to raise funds either through equity or debt. Top 3 Catalist Stocks With Strongest 5-Year Market Capitalisation Growth Singapore Medical Group, Moya Holdings Asia, and 800 Super Holdings are three Catalist stocks with a  market capitalisation above S$100 million that saw the strongest market capitalisation growth over the past five years (Oct 2012 to-date, excluding reverse takeovers). The three stocks have an average market capitalisation of S$258.1 million and have an average PE ratio of 33.0x. Some highlights include:  Market Capitalisation Growth Over Last 5 Years (S$M) Source: Bloomberg (data as of 19 October 2017). Note: For market capitalisation above S$100 million and excludes reverse takeovers (RTOs). 
Name SGX Code Market Cap S$M Last Price* Price Change YTD % P/E (x) P/B (x) ROE %
Singapore Medical Group 5OT 278 0.615 41.4 37.7 3.1 12.0
Moya Holdings Asia 5WE 274 0.098 84.9 48.3 2.2 4.8
800 Super Holdings 5TG 222 1.240 28.5 12.9 2.7 22.6
Average       51.6 33.0 2.7 13.1
Source: Bloomberg & SGX StockFacts (data as of 19 October 2017). *Last price of companies are denoted in their respective trading currencies.  Singapore Medical Group (market cap S$278.0 million) Stock Performance and Valuations
  • Singapore Medical Group registered +41.4% price gains in 2017 year-to-date. Its market capitalisation grew 17.4 times from S$16.0 million to S$278.0 million from Oct 2012 to-date.
  • From a valuation perspective, the stock currently trades at 37.7x PE ratio and 3.1x PB ratio (both trailing), with a forecasted ROE of 24.3% for FY2017 according to consensus from Bloomberg.
 Recent Earnings Release and Management Outlook
  • Singapore Medical Group reported a net profit of S$4.0 million for 1H2017. Revenue of S$30.7 million for 1H2017 was 57.5% higher YoY, driven by the Group’s Healthcare segment. The Group also reported a S$11.6 million net cash position.
  • Executive Director and CEO Dr. Beng Teck Liang commented that inorganic and organic growth strategies through acquisitions have contributed to strong 1H2017 results, and focus for 2H2017 will be on integrating their newly acquired entities while driving operational efficiencies in staffing, marketing and space utilisation. The full statement can be read here.
  • On 19 Oct, the Group announced the acquisition of hospital-based paediatric clinic for S$7.9 million, expanding the Group’s portfolio of clinics to 36. Click here to read more.
Key Highlights
  • Singapore Medical Group is a private specialist healthcare provider with 25 specialties, 36 clinics and SMG Associate clinics. The Group continues to set sights on inorganic and organic growth as part of their overarching growth strategy. It plans to expand into new segments such as Cardiology.
  • Post their entry into the paediatric discipline in Apr 2017 through acquisitions of Toa Payoh and Bishan clinics and its first hospital-based clinic at Mount Alvernia, the Group plans to further grow this segment and add a fourth specialist by 1Q2018. It is now one of the largest in the private sector dedicated towards women’s health and wellness, babies and children.
 Moya Holdings Asia (market cap S$274.5 million) Stock Performance and Valuations
  • Moya Holdings Asia registered +84.9% price gains in 2017 year-to-date. Its market capitalisation grew 8.6 times from S$32.1 million to S$274.5 million from Oct 2012 to-date.
  • From a valuation perspective, the stock currently trades at 48.3x PE ratio and 2.2x PB ratio (both trailing), with a forecasted 8.6% ROE for FY2017 according to consensus from Bloomberg.
 Recent Earnings Release and Management Outlook
  • Moya Holdings Asia reported a net profit of S$2.5 million for 1H2017, compared to a net loss of S$0.3 million a year ago. Revenue of S$28.4 million for 1H2017 was 307% higher YoY, mainly attributed to higher percentage of completion achieved for the construction revenue of the build-operate-transfer (BOT) projects and contribution of water sales from the Tangerang BOT project and the Acuatico Group.
  • CEO Mr. Mohammad Syahrial commented that the Group will continue to execute BOT water treatment plants located in Bekasi Regency and Tangerang City to achieve sustainable growth while looking to expand business reach and capacity in Indonesia through merger and acquisitions. Click here to read more.
  • On 11 Jun, the Group announced the acquisition of Acuatico Pte. Ltd. for US$245.2 million. The Group believes the acquisition will increase the Group’s production capacity by more than four times and expand business reach. Click here to read more.
Key Highlights
  • Moya Holdings Asia mainly engages in the investment and development of total water solutions in Indonesia which includes collection of raw water, treatment of captured water and distribution of clean water.
  • With the acquisition of Acuatico, the Group believes it to be one of leading private players in Indonesia’s water treatment industry with a total water treatment capacity of 13,935 litres per second and the acquisition to contribute significant improvement in the Group’s overall earnings.
800 Super Holdings (market cap S$221.7 million) Stock Performance and Valuations
  • 800 Super Holdings registered +28.5% price gains in 2017 year-to-date. Its market capitalisation grew 6.4 times from S$34.9 million to S$221.7 million from Oct 2012 to-date.
  • From a valuation perspective, the stock currently trades at 12.9x PE ratio and 2.7x PB ratio (both trailing), with a forecasted 19.1% ROE for FY2018 according to consensus Bloomberg.
 Recent Earnings Release and Management Outlook
  • 800 Super Holdings reported a profit before tax of S$20.8 million for FY2017, 11.6% higher YoY. Revenue of S$156.9 million for FY2017 was 0.3% higher YoY, mainly due to the award of new contracts, notwithstanding the completion of certain cleaning contracts.
  • Executive Chairman Mr. Lee Koh Yong commented that the group had maintained stable development of its business in FY2017 and will capitalise on new business opportunities that may arise. He believes that its strong foundations will pave the way for long-term sustainable growth. The full statement can be read here.
  • On 3 Oct, the Group announced the proposed acquisition of Iwash Laundry (Senoko) Pte. Ltd. for S$5.0 million. The Group views the proposed acquisition as beneficial to allow the Group to venture into alternative new growth areas and opportunities. Click here to read more.
Key Highlights
  • 800 Super Holdings is an established environmental services provider for public and private sectors in Singapore. Its services include waste management, cleaning and conservancy and horticultural services.
  • The Group’s waste-to-energy (WTE) plant at Tuas South, as part of its diversification into downstream waste treatment, is expected to operate by the end of 2017. When operational, the WTE plant will supply green electricity to the Group’s on-site operations located in the vicinity and is expected to provide additional headroom for future growth.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the “SGX Group Companies”) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore.  The information in this document is subject to change without notice. This document may only be onward disseminated by the recipient wholly or in part if its content is attributed to SGX. This document shall not otherwise be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.”
Read the full article
By SGX My Gateway
LEAVE A COMMENT
LEAVE A COMMENT

Your email address will not be published.

*

Your Email Address will not be published
*

Read More Articles
More from thefinance